Throat cancer showdown: radiation vs. surgery in HPV patients
NCT ID NCT03210103
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two standard treatments—radiation therapy and surgery—for people with HPV-related throat cancer. The goal is to see which approach provides better survival and quality of life. About 61 adults with early-stage cancer are taking part to help guide future treatment choices.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
61 people
The number who actually took part.
- Started
-
Jan 2018
- Expected to finish
-
Aug 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 years or older * willing to provide informed consent * ECOG performance status 0-2 * Histologically confirmed squamous cell carcinoma * P16 positive, or HPV positive * Primary tumor site in the oropharynx (includes tonsil, soft palate, base of tongue, walls of oropharynx) * Eligible for curative intent treatment, with likely negative resection margins at surgery. For patients where adequate transoral access is in question, they will first undergo an examination under anesthesia prior to randomization to ensure adequate exposure can be obtained. * Smokers and non-smokers are included. Patients will be stratified by ,\<10 pack years smoking history versus \> or equal to 10 pack years. * Tumor stage (AJCC 8th edition): T1 or T2 * Nodal stage (AJCC 8th edition): N0, N1, or N2 * For patients who may require chemotherapy (ie, patients with multiple lymph nodes positive or a single node more than 3 cm in size, in any plane, CBC/differential within 4 weeks prior to randomization with adequate bone marrow function, hepatic, and renal function defined as: Hemoglobin ≥ 80 g/L; Absolute neutrophil count ≥ 1.5 x 10 9/L, platelets ≥ 100 x 10 9/L, bilirubin ≤ 35 umol/L, AST or ALT ≤ 3 x the upper limit of normal; serum creatinine ≤ 130 umol/L or creatinine clearance ≥ 50 ml/min * patients assessed at head and neck multidisciplinary clinic (with assessment by radiation oncologist and surgeon) and presented at multidisciplinary tumor board prior to randomization Exclusion Criteria: * unambiguous clinical or radiological evidence of extranodaal extension on pre-treatment imaging. This includes the presence of matted notes, defined as 3 or more nodes that are abutting with loss of intervening fat planes * Serious medical comorbidities or other contraindications to radiotherapy, chemotherapy or surgery * prior history of head and neck cancer within 5 years * prior head and neck radiation at any time * metastatic disease * inability to attend full course of radiotherapy or follow up visits * prior invasive malignant disease unless disease-free for at least 5 years or more, with the exception of non-melanoma skin cancer * pregnant or lactating women
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV positive oropharyngeal squamous cell carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
BC Cancer
Vancouver, British Columbia, V5Z 1G1, Canada
-
Gold Coast University Hospital
Gold Coast, Queensland, Australia
-
Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
-
London Regional Cancer Program
London, Ontario, N6A 4L6, Canada
-
Ottawa Hospital Research Institute
Ottawa, Ontario, K1Y 4E9, Canada
-
Royal Adelaide Hospital
Adelaide, Australia
-
Sunnybrook Research Institute
Toronto, Ontario, M4N 3M5, Canada
-
Tom Baker Cancer Centre
Calgary, Alberta, T2N 4N2, Canada
-
University Health Network
Toronto, Ontario, M5G 2C4, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can steroids, a migraine drug, or tongue exercises save nerves after throat cancer treatment?
- MRI scans may reveal which throat cancer patients need stronger treatment
- Can a DNA vaccine boost immunotherapy against HPV-Linked head and neck cancer?
- Blood test may tailor throat cancer treatment, sparing patients from harsh side effects
- Robotic surgery may spare throat cancer patients from chemo and radiation
- Vaccine trains immune system to fight HPV-Positive head and neck tumors